Armando Santoro

TL;DR: Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorAFenib.

TL;DR: It is demonstrated that for advanced soft tissue sarcoma, response to chemotherapy is not predicted by the same factors as is overall survival time and needs to be taken into account in the interpretation of trials assessing the value of new agents for this disease on the basis of response to treatment.

TL;DR: In advanced soft tissue sarcoma patients for whom significant tumor volume reduction may be an important end point of a chemotherapy regimen, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared.

TL;DR: Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC, and AEs matched the known safety profiles of both agents, but rates of rash/desquamation, anorexia, and diarrhea were higher in the sorafanib/erlotinIB arm, whereas rates of alopecia and hand-foot skin reaction were higherIn the sorAFenib/placebo arm.

TL;DR: With extended follow-up, responses to nivolumab were frequent and durable and seems to be associated with a favorable safety profile and long-term benefits across a broad spectrum of patients with relapsed/refractory cHL.